Targeting DGKG can enhance the efficacy of dual blockade of PD-1 and VEGFR-2 therapies [154].Therefore, besides direct tumor-killing strategies, attempting to inhibit tumor growth by targeting tumor angiogenesis might be a more moderate, effective, and less resistance-prone approach. The gene discussed is KDR; the disease is neoplasm.